American Society of Hematology

Figure 2

Biodistribution of 131I-BC8 (anti-CD45) and 125I-BHV-1 (control) in a human T-NHL xenograft model. Biodistributions quantified as percentage injected radioiodine dose/g tissue (%ID/g) of 131I-BC8 (anti-CD45, ■) and 125I-BHV-1 (control, ) in mice with CCRF-CEM (A,B) and Karpas 299 (C,D) xenografts after 24 and 48 hours.

Biodistribution of ¹³¹I-BC8 (anti-CD45) and ¹²⁵I-BHV-1 (control) in a human T-NHL xenograft model. Biodistributions quantified as percentage injected radioiodine dose/g tissue (%ID/g) of ¹³¹I-BC8 (anti-CD45, ■) and ¹²⁵I-BHV-1 (control, ) in mice with CCRF-CEM (A,B) and Karpas 299 (C,D) xenografts after 24 and 48 hours.

This Feature Is Available To Subscribers Only